What is the PCAC? The advisory committee between peptides and FDA approval

If you’ve spent the last six months on peptide forums, you’ve seen the letters PCAC attached to a date — July 23 to 24, 2026 — and a vague sense that something important is about to happen. The framing is usually breathless. The detail is usually wrong.

PCAC stands for the Pharmacy Compounding Advisory Committee. It’s an FDA panel whose July meeting will recommend which of seven peptides US compounding pharmacies may dispense by prescription. Five more are queued for a second meeting before the end of February 2027. The vote is not an approval, and it isn’t the end of the conversation. What it is — and isn’t — is worth getting straight.

What PCAC actually is

The Pharmacy Compounding Advisory Committee is a standing FDA advisory body with one specific job: tell the agency which substances should be allowed onto the Section 503A bulk drug substances list. Section 503A is the part of federal law that governs traditional pharmacy compounding — the lane where a licensed pharmacist makes a drug to fill a prescription for a named patient when no approved commercial product fits the prescribing need.

The committee is advisory. That word does work. PCAC does not approve drugs and does not write rules. It reviews a nomination, takes public comment, and recommends a position to the FDA. The FDA then makes the actual decision through formal rulemaking — usually months later. The vote is the data point the FDA uses to write the rule, not the rule itself.

What makes PCAC matter right now is that the panel is being asked to consider a group of peptides as a coherent batch — twelve compounds across two meetings, all currently sold off-label through research-chemical vendors. The committee’s recommendations will shape whether those compounds end up dispensable by prescription through a licensed US pharmacy, or whether they stay outside the regulated supply chain.

How the process works

A substance gets onto the docket through a formal nomination — usually by a compounding pharmacy, a prescriber, or an industry group — for use in compounded prescriptions at a named indication. FDA staff build a record, then publish a Federal Register notice opening a public docket and a meeting date. The committee meets in public, hears FDA staff presentations and outside testimony, deliberates, and votes.

The FDA then decides what to do with the recommendation through rulemaking — a proposed rule, another comment period, a final rule. None of it is fast. A favourable PCAC vote in July 2026 does not mean a peptide is dispensable from a US pharmacy in August 2026. It means the case moves forward. An unfavourable vote can effectively close the compounding lane, since FDA rarely lists a compound PCAC has recommended against.

What the July 2026 meeting is reviewing

The April 2026 Federal Register notice 2026-07361 sets the agenda for two days at FDA’s White Oak campus in Silver Spring. The per-peptide uses evaluated indications below are read off the FDA advisory-committee calendar page for the meeting. Seven peptides, split across two sessions, each with a specific FDA-reviewed indication.

On July 23 the committee evaluates four compounds. BPC-157, the gastric-derived peptide that dominates injury-recovery forums, is on the docket for ulcerative colitis — drawing on its mucosal-protection research, not its tendon-repair marketing. KPV, a tripeptide fragment of alpha-melanocyte-stimulating hormone, is on for wound healing and inflammatory conditions. TB-500 is on for wound healing. MOTs-C, sold as a longevity stack ingredient, is on for obesity and osteoporosis.

On July 24 the committee evaluates three more. Emideltide — also called delta sleep-inducing peptide, or DSIP — is on for opioid withdrawal, chronic insomnia, and narcolepsy. Semax is on for cerebral ischemia, migraine, and trigeminal neuralgia. Epitalon, marketed across the longevity supplement market as a telomere-biology compound, is on for insomnia.

Read those indications carefully. They are not what the off-label market sells these compounds for. MOTs-C for obesity not longevity, Epitalon for insomnia not telomere maintenance — several sit at right angles to the marketing pitch the buyer has seen.

What the February 2027 meeting is reviewing

The same April 2026 FDA action scheduled a second PCAC meeting before the end of February 2027 to review five more bulk drug substances. The exact date has not been published as of mid-2026, but the list is set: Dihexa acetate, LL-37, GHK-Cu, PEG-MGF, and Melanotan II.

The GHK-Cu entry has a detail worth flagging, and it is the sharpest example in the docket of how route of administration matters. The FDA split GHK-Cu by route, and the two halves moved in opposite directions on the 503A bulk substances lists. Injectable GHK-Cu — the form the off-label market actually sells — came off Category 2, the FDA’s do not compound / significant-safety-concerns list. Non-injectable GHK-Cu went the other way: it was pulled out of Category 1, the under evaluation list that had temporarily let pharmacies compound it under enforcement discretion, so topical GHK-Cu actually lost a safe harbor it used to have. Both forms are slated for the February 2027 consultation. The committee will be asked about both, but the substantive question is about the injection use — the route that just moved off the banned list and is what most buyers of GHK-Cu off research-chemical sites are doing with it.

The other four are similar in shape to the July line-up — peptides with active off-label markets, routed to PCAC for compounding-pathway eligibility. Same advisory-vote-then-rulemaking flow, eight months later.

What a PCAC vote does not establish

This is the part forum coverage almost always flattens. A favourable PCAC recommendation is not an FDA approval. The marketed-drug approval pathway runs through Investigational New Drug applications, Phase 1–3 trials, and a New Drug Application or Biologics License Application. None of that has been completed for any of the twelve peptides on the two dockets, and none will be by July 2026 or February 2027.

What a favourable vote does establish is that the substance may be dispensed in compounded prescriptions by a US-licensed pharmacy under Section 503A, for the specific indication the committee evaluated — not for whatever the supplement market is selling it for. A compounded BPC-157 prescription for ulcerative colitis would sit on a clear regulatory floor. A compounded BPC-157 prescription for a torn shoulder would be off-label use of a compounded drug — a greyer position the supervising physician would have to decide. The off-label uses that drive most of the demand sit outside what the committee actually voted on.

Why this matters for someone reading about peptides today

Right now, the dominant supply chain for the twelve peptides on these two dockets runs through research-chemical sites — vials labelled not for human consumption, no third-party testing, no prescription, no supervising physician. The PCAC review is the formal regulatory gate between that supply chain and a different one: a US physician’s prescription, a US-licensed compounding pharmacy, a named indication on the label.

A favourable vote followed by favourable FDA rulemaking opens that second supply chain for the indications under review. An unfavourable result leaves the existing situation unchanged. The July meeting is the first real signal on which path the FDA will take across this group of peptides.

If you actually take one of these compounds, the question is not will it get approved. It’s will my supervising physician be able to write me a prescription for it through a licensed pharmacy after July, after February, or not at all.

When the legitimate version exists

Wolverine Health is being built around the moment that regulated supply chain opens — physician-supervised protocols, US-licensed compounding pharmacies, every batch third-party tested. Join the waitlist for a heads-up the moment the pathway is real for the peptide you’re tracking.